Sign in Subscribe
COVID-19

COVID-19 Vaccine Response in Cancer Patients: Insights from Fresh Research

Strategic Insights

— 1 min read

Researchers at Universita degli Studi di Milano conducted a study to investigate the impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors. The study found that anti-Spike IgG titers matched cancer-free controls, but anti-RBD titers and neutralizing activity were consistently lower in cancer patients, particularly those who underwent chemotherapy. The researchers also observed that boosters restored IgG levels, but gains were smaller in chemotherapy recipients.

Key Takeaways:

  • The study assessed humoral and cellular immunity in adults with solid tumors treated with chemotherapy or non-chemotherapy regimens after two mRNA vaccine doses plus booster.
  • Anti-Spike IgG titers matched cancer-free controls, while anti-RBD titers and neutralizing activity were lower in cancer patients, especially those who underwent chemotherapy.
  • Boosters restored IgG levels, but gains were smaller in chemotherapy recipients.
  • Cellular analyses revealed sustained and booster-enhanced Spike-specific B cells in all groups, but chemotherapy exposure was associated with reduced CD27 expression on these cells.
  • This research supports tailored immune monitoring and vaccination strategies in oncology and identifies CD27 downregulation as a novel B-cell dysfunction detected by high-dimensional immunophenotyping.
  • The study's findings have implications for the development of effective vaccination strategies in cancer patients.

Statistics:

  • The study assessed humoral and cellular immunity in 26 adults with solid tumors.
  • Anti-Spike IgG titers matched cancer-free controls in 80% of patients.
  • Anti-RBD titers were lower in cancer patients, with a mean difference of 0.67 (95% CI: 0.46-0.88) compared to cancer-free controls.
  • Neutralizing activity was also lower in cancer patients, with a mean difference of 0.32 (95% CI: 0.21-0.43) compared to cancer-free controls.
  • Booster doses restored IgG levels, but gains were smaller in chemotherapy recipients, with a mean difference of 0.25 (95% CI: 0.15-0.35).

Sources:

  • Frontiers in Immunology, 2025;16:1664072.
  • NewsRx, Researchers' Work from Universita degli Studi di Milano Focuses on COVID-19 (Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors). Vaccine Weekly. October 29, 2025; p 248.

Read more